Literature DB >> 14594113

Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.

A Gambineri1, U Pagotto, M Tschöp, V Vicennati, E Manicardi, A Carcello, M Cacciari, R De Iasio, R Pasquali.   

Abstract

In a previous study we were the first to describe a negative correlation between circulating ghrelin concentrations and androgen levels in human plasma, suggesting an interaction between ghrelin and the endocrine regulation of reproductive physiology. We now investigated a potential direct regulatory influence of circulating androgens on plasma ghrelin levels. Fourteen obese women with polycystic ovary syndrome (PCOS) on a hypocaloric diet were randomly assigned to treatment groups (open-labeled design), receiving either placebo (no.=7) or the antiandrogen flutamide (no.=7) for 6 months. Anthropometry, visceral (VAT) and subcutaneous (SAT) adipose tissue (quantified by computerized tomography), plasma hormone levels, insulin sensitivity indexes (Quantitative Insulin-Sensitivity Check Index-QUICKI) and Homeostatic Model Assessment applied to the oral glucose tolerance test (HOMA(OGTT)) were evaluated at baseline and at the end of the study. Body weight decreased and insulin resistance indexes improved in both groups. A tendency toward a greater loss of VAT was observed in the flutamide group. Only in the flutamide group was a significant reduction of androgens levels observed. Plasma ghrelin levels significantly increased following treatment with flutamide, while ghrelin remained unchanged in the placebo group. We observed a negative correlation between changes of ghrelin levels and changes of androgen plasma concentration in the flutamide-treated group. In the same group a positive correlation was found between plasma ghrelin changes and insulin sensitivity as expressed by HOMA(OGTT). Analysis in a multiple regression model, however, showed that plasma ghrelin changes were mainly due to changes of androgen levels rather than improved insulin sensitivity. We, therefore, conclude that androgens are independent modulators of circulating ghrelin concentrations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594113     DOI: 10.1007/BF03347020

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  Ghrelin induces adiposity in rodents.

Authors:  M Tschöp; D L Smiley; M L Heiman
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

2.  Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion.

Authors:  Tomomi Shiiya; Masamitsu Nakazato; Masanari Mizuta; Yukari Date; Muhtashan S Mondal; Muneki Tanaka; Shin-Ichi Nozoe; Hiroshi Hosoda; Kenji Kangawa; Shigeru Matsukura
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

Review 3.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

4.  Growth hormone secretagogue binding sites in peripheral human tissues.

Authors:  M Papotti; C Ghè; P Cassoni; F Catapano; R Deghenghi; E Ghigo; G Muccioli
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

5.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Immunolocalization of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in the cyclic human ovary.

Authors:  F Gaytan; M L Barreiro; L K Chopin; A C Herington; C Morales; L Pinilla; F F Casanueva; E Aguilar; C Diéguez; M Tena-Sempere
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

8.  Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome.

Authors:  Andrea M Haqq; I Sadaf Farooqi; Stephen O'Rahilly; Diane D Stadler; Ron G Rosenfeld; Katherine L Pratt; Stephen H LaFranchi; Jonathan Q Purnell
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

9.  Circulating ghrelin levels in patients with polycystic ovary syndrome.

Authors:  Christof Schöfl; Rüdiger Horn; Thilo Schill; Hans W Schlösser; Manfred J Müller; Georg Brabant
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

10.  Ultrasonic findings in polycystic ovarian disease.

Authors:  L F Orsini; S Venturoli; R Lorusso; V Pluchinotta; R Paradisi; L Bovicelli
Journal:  Fertil Steril       Date:  1985-05       Impact factor: 7.329

View more
  15 in total

Review 1.  Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism.

Authors:  Diego Perez-Tilve; Ruben Nogueiras; Federico Mallo; Stephen C Benoit; Matthias Tschoep
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis.

Authors:  C Merlotti; V Ceriani; A Morabito; A E Pontiroli
Journal:  Int J Obes (Lond)       Date:  2017-02-02       Impact factor: 5.095

3.  Abnormal ghrelin secretion contributes to gastrointestinal symptoms in multiple system atrophy patients.

Authors:  Tetsutaro Ozawa; Jun Tokunaga; Musashi Arakawa; Atsushi Ishikawa; Ryoko Takeuchi; Naomi Mezaki; Takeshi Miura; Naoko Sakai; Mariko Hokari; Akari Takeshima; Kota Utsumi; Takashi Kondo; Akio Yokoseki; Masatoyo Nishizawa
Journal:  J Neurol       Date:  2013-05-08       Impact factor: 4.849

4.  Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal-weight men.

Authors:  A Gambineri; U Pagotto; R De Lasio; M C Meriggiola; A Costantino; L Patton; C Pelusi; G Pelusi; R Pasquali
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

Review 5.  Sex differences in the physiology of eating.

Authors:  Lori Asarian; Nori Geary
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-31       Impact factor: 3.619

6.  Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.

Authors:  Aimee S L Caldwell; Melissa C Edwards; Reena Desai; Mark Jimenez; Robert B Gilchrist; David J Handelsman; Kirsty A Walters
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

Review 7.  Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Juan Pablo Domecq; Gabriela Prutsky; Rebecca J Mullan; Vishnu Sundaresh; Amy T Wang; Patricia J Erwin; Corrine Welt; David Ehrmann; Victor M Montori; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2013-10-03       Impact factor: 5.958

8.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

9.  The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women.

Authors:  Rita Rastogi Kalyani; Manuel Franco; Adrian S Dobs; Pamela Ouyang; Dhananjay Vaidya; Alain Bertoni; Susan M Gapstur; Sherita Hill Golden
Journal:  J Clin Endocrinol Metab       Date:  2009-09-29       Impact factor: 5.958

10.  Total ghrelin levels during acute insulin infusion in patients with polycystic ovary syndrome.

Authors:  D Micic; M Sumarac-Dumanovic; A Kendereski; G Cvijovic; S Zoric; D Pejkovic; J Micic; N Milic; C Dieguez; F F Casanueva
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.